Clinical characteristics of 10 patients with marginal zone B cell lymphoma with IgG4-positive plasma cells
| Patient no. | Age (years)/gender | Laterality | Clinical stage* | Initial treatment | Events during follow-up | Second treatment | Outcome and follow-up (months) |
| 1 | 66/M | Bilateral | T2cN4M0/III | Radiation | Malignant transformation to diffuse large cell type | CHOP and rituximab | Died from disease (36) |
| 2 | 66/M | Left | T2cN0M0/IE | Radiation | Orbital LPI; gastric LPI | rituximab | AOD (97) |
| 3 | 67/F | Left | T2cN0M0/IE | Radiation | Gastric carcinoma and LPI, developing TNM staging N4 | Gastrectomy, CHOP and rituximab | AOD (70) |
| 4 | 75/M | Left | T2cN0M0/IE | Radiation | Developing TNM staging N4 | ND | Died from other cause (65) |
| 5 | 64/F | Left | T2bN0M0/IE | CP | Developing TNM staging N3 | ND | AWD (82) |
| 6 | 70/M | Right | T2cN4M0/III | Excision | None | ND | AWD (13) |
| 7 | 61/M | Left | T2cN0M0/IE | Radiation | Developing TNM staging N4 | ND | AWD (73) |
| 8 | 90/M | Left | T2cN4M0/III | Radiation | None | ND | AOD (9) |
| 9 | 65/M | Right | T2bN0M0/IE | Radiation | None | ND | AOD (26) |
| 10 | 64/M | Right | T2cN0M0/IE | Radiation | None | ND | AOD (26) |
↵* American Joint Committee on Cancer staging and Ann Arbor staging.
AOD, alive without disease; AWD, alive with disease; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; LPI, lymphoplasmacytic infiltrations; TNM, tumour, node, metastases.